Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Clinuvel Pharmaceuticals Limited

Biosensis is involved in the development and supply of biological reagents and assay kits for research and diagnostic applications, including ELISA assays and antibodies.

Biosensis

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

MEI Pharma, Inc.

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Leon Serry

Megan Baldwin

Opthea Limited

CLINUVEL develops pioneering treatments for patients with severe, unmet medical needs, translating scientific concepts and breakthroughs into commercial products.

Metric
Company Name	Clinuvel Pharmaceuticals Limited	Biosensis	MEI Pharma, Inc.	Opthea Limited
Symbol	CUV		MEIP	OPT
MSH ID	COM:CLINUVEL	COM:BIOSENSIS	COM:MEIPHARMA	COM:OPTHEA
Market	STOCKS	PRIVATE	STOCKS	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	AU	AU	US	AU
Stage
Employee Count	16		46	24
Website	clinuvel.com	biosensis.com	meipharma.com	opthea.com
LinkedIn				opthea
Founders

Metric
Market Cap	481.89M	18.59M	281.28M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	56.34M	65.30M	124.67K
Revenue (LTM)
Revenue (NTM)
Gross Profit	49.90M	65.30M	124.67K
EBITDA	35.96M	14.54M	-187.96M
Operating Income	35.23M	14.54M	-191.84M
Net Income	22.77M	17.78M	-220.24M
EPS	0.45	2.67	-0.35
Diluted EPS	0.44	2.67	-0.35
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.76	0.99	0.56
Operating Profit Margin	0.53	0.34	-1.41K
EBITDA Margin	0.64	0.22	-1.51K
Net Profit Margin	0.41	0.39	-1.38K
Return on Equity	0.19	0.48	8.77
Return on Assets	0.15	0.43	-1.00
Return on Capital Employed	0.22	0.44	-1.27

COM:CLINUVEL

CLINUVEL

Last Close

13.04

25/11 05:10

Market Cap

754.17M

Beta: -

Volume Today

142.47K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	26.62	0.69	-0.92
P/B Ratio	4.95	0.36	-22.76
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	10.72	0.36	4.32K
EV Multiple	22.57	1.05	-1.48

Metric
Days Sales Outstanding	103.53		22.10K
Days Payables Outstanding	135.48
Days Inventory Outstanding	188.05
Operating Cycle	297.33		24.45K
Cash Conversion Cycle	255.83	-262.44	-42.88K
Asset Turnover	0.38	1.58	0.00

Metric
Operating Cash Flow	23.68M	-50.47M	-161.02M
Free Cash Flow	20.11M	-50.48M	-161.05M
Cash Flow to Debt	118.80		-0.68
Operating Cash Flow/Sales	0.52	-0.66	-1.03K
Free Cash Flow Yield	0.05	-1.92	-0.53

Metric
Cash & Equivalents	117.49M	3.71M	172.47M
Accounts Receivable	-2.57M
Inventory	6.79M
Goodwill
Debt to Capitalization	0.01	0.19	2.15
Debt to Assets	0.01	0.12	0.00
Current Ratio	7.44	10.32	5.28
Quick Ratio	8.39	7.40	5.15

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.11	0.02	53.82
R&D to Revenue	0.02	0.35	1.13K
SG&A to Revenue	0.02	0.31	256.83